A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis

The purpose of this study is to evaluate the safety and efficacy using placenta derived decidual stromal cell therapy for hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. It is hypothesized that the decidual stromal cell therapy is safe to infuse and that they have a positive clinical effect.

Patients with grade 2-4 hemorrhagic cystitis will receive decidual stromal cell therapy at approximately 1-2x10^6 cells/kg once or at weekly intervals dependent on clinical effect.

Inclusion Criteria:

• Hemorrhagic cystitis grade 2-4

Exclusion Criteria:

• Urinary urge without macroscopic hematuria or clots